The concept of drug repurposing has gained substantial momentum in oncology research over the past several years. Rather than developing entirely new compounds through lengthy and expensive clinical pipelines, scientists are revisiting existing medications with well-established safety profiles to explore their potential anticancer properties. Among the most discussed candidates in this emerging field are benzimidazole antiparasitic agents, particularly fenbendazole, which has generated both scientific curiosity and public attention following anecdotal reports and a growing body of preclinical evidence.
